Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
03
02
2021
revised:
27
03
2021
accepted:
30
04
2021
pubmed:
6
5
2021
medline:
1
4
2022
entrez:
5
5
2021
Statut:
ppublish
Résumé
Invasive mucinous adenocarcinoma (IMA) is a unique subtype of lung adenocarcinoma, characterized genomically by frequent A total of 200 IMAs were analyzed by 410-gene DNA next-generation sequencing (MSK-IMPACT; Combined MSK-IMPACT and MSK-Fusion testing identified mutually exclusive driver alterations in 96% of IMAs, including This is the largest molecular study of IMAs to date, where we demonstrate the presence of a major oncogenic driver in nearly all cases. This study is the first to document more aggressive characteristics of
Identifiants
pubmed: 33947695
pii: 1078-0432.CCR-21-0423
doi: 10.1158/1078-0432.CCR-21-0423
pmc: PMC8282731
mid: NIHMS1702953
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4066-4076Subventions
Organisme : NCI NIH HHS
ID : P01 CA129243
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Clin Cancer Res. 2014 Jun 15;20(12):3087-93
pubmed: 24727320
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Cancer. 2011 Sep 15;117(18):4257-66
pubmed: 21387273
J Mol Diagn. 2017 Mar;19(2):244-254
pubmed: 28027945
Clin Cancer Res. 2012 Nov 15;18(22):6169-77
pubmed: 23014527
Oncogene. 2002 Dec 5;21(55):8442-52
pubmed: 12466964
Clin Cancer Res. 2019 Aug 1;25(15):4712-4722
pubmed: 31028088
Methods Mol Biol. 2016;1392:71-82
pubmed: 26843048
Cancer. 2010 Feb 1;116(3):670-5
pubmed: 20029977
Clin Cancer Res. 2012 Sep 15;18(18):4910-8
pubmed: 22761469
Oncogene. 2020 Jan;39(3):487-502
pubmed: 31519989
Cancer Discov. 2014 Apr;4(4):415-22
pubmed: 24469108
Clin Transl Gastroenterol. 2016 Mar 24;7:e157
pubmed: 27010960
J Thorac Oncol. 2020 Jun;15(6):948-961
pubmed: 32036070
J Thorac Oncol. 2016 Mar;11(3):414-9
pubmed: 26723242
Clin Cancer Res. 2019 Aug 15;25(16):4966-4972
pubmed: 30988082
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Clin Cancer Res. 2019 Aug 1;25(15):4674-4681
pubmed: 31068372
J Thorac Oncol. 2010 Jun;5(6):830-6
pubmed: 20521350
Cancer Discov. 2020 May;10(5):674-687
pubmed: 32213539
Mod Pathol. 2011 May;24(5):653-64
pubmed: 21252858
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Am J Clin Pathol. 2020 Jun 8;154(1):88-102
pubmed: 32215558
J Thorac Oncol. 2010 Aug;5(8):1197-200
pubmed: 20661086
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
J Thorac Oncol. 2017 Mar;12(3):446-457
pubmed: 27903463
Oncotarget. 2016 Aug 26;8(36):60094-60108
pubmed: 28947956
Lung Cancer. 2016 Dec;102:82-88
pubmed: 27987593
Nat Med. 2014 Dec;20(12):1479-84
pubmed: 25384085
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Mod Pathol. 2021 Apr;34(4):786-797
pubmed: 33024306
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Cancer Discov. 2018 Jun;8(6):686-695
pubmed: 29610121
J Clin Oncol. 2018 Aug 20;36(24):2532-2537
pubmed: 29989854
Transl Lung Cancer Res. 2017 Oct;6(5):508-512
pubmed: 29114467
J Mol Diagn. 2011 Jan;13(1):64-73
pubmed: 21227396
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer Discov. 2018 Sep;8(9):1087-1095
pubmed: 29802158
J Thorac Oncol. 2015 Aug;10(8):1156-62
pubmed: 26200269
Hum Pathol. 2013 Dec;44(12):2636-42
pubmed: 24119562